Statement of Retraction: Novel Sunifiram carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist simulation-guided analogue design and pharmacological screening.

Author unknown

Open source

DOI
10.1080/14756366.2026.2712703
Published
2026 Dec
Container
Journal of enzyme inhibition and medicinal chemistry
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/14756366.2026.2712703,
  title = {Statement of Retraction: Novel Sunifiram carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist simulation-guided analogue design and pharmacological screening.},
  year = {2026},
  journal = {Journal of enzyme inhibition and medicinal chemistry},
  doi = {10.1080/14756366.2026.2712703},
  url = {https://doi.org/10.1080/14756366.2026.2712703}
}

RIS

TY  - JOUR
TI  - Statement of Retraction: Novel Sunifiram carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist simulation-guided analogue design and pharmacological screening.
PY  - 2026
JO  - Journal of enzyme inhibition and medicinal chemistry
DO  - 10.1080/14756366.2026.2712703
UR  - https://doi.org/10.1080/14756366.2026.2712703
ER  - 

APA

Statement of Retraction: Novel Sunifiram carbamate hybrids as potential dual acetylcholinesterase inhibitor and NMDAR co-agonist simulation-guided analogue design and pharmacological screening.. (2026). Journal of enzyme inhibition and medicinal chemistry. https://doi.org/10.1080/14756366.2026.2712703

Source records